The Janus Henderson Alternatives grouping includes teams with different areas of focus and approach. The Diversified Alternatives Team brings together a cross-asset class combination of alpha generation, risk management, and efficient beta replication strategies. These include multi-strategy, liquid alternatives, agriculture, and global commodities/managed futures.


Diversified Alternatives

The Janus Henderson Diversified Alternatives Team believes the purpose of Alternative investing is to improve a clients’ risk-return trade-off by providing diversification relative to traditional asset class investments. The team offer solutions aimed at improving clients’ efficient frontiers through global, multi-asset Alternative Risk Premia, Hedge Fund Risk Premia, Enhanced Equity and Commodity Index solutions.


Balloon pop

Diversified Alternatives 2020 outlook: Out of the Goldilocks zone?

December 17, 2019

Will 2019 be considered the last hurrah? Could 2020 mark the beginning of a new era of volatility for global markets? David Elms, Head of Diversified Alternatives, gives some insight into where he sees the most attractive areas of opportunity, and what this might mean for investors.

Read More

Portfolio rebalancing – pick a different day

December 12, 2019

The majority of asset allocation models are rebalanced on the last day of the calendar month, but is this the best approach to maximize returns? Portfolio manager Aneet Chachra and David Elms, Head of Diversified Alternatives, tested the validity of this traditional market orthodoxy, with some surprising results.

Read More

Investors possibly ill-positioned for continued market rotation

December 2, 2019

Investors may not be sufficiently considering the prospects of a steadying US economy and a potential rise in inflation.

Read More

In-depth feature

Test tubes | Navigating the drug pricing debate | Janus henderson Investors

Navigating the drug pricing debate

August 3, 2018 | Comments Off on Navigating the drug pricing debate

When the Trump administration introduced a ‘blueprint’ to lower drug prices in May, the pharmaceutical industry breathed a sigh of relief. Andy Acker and Ethan Lovell, Portfolio Managers of the Global Life Sciences strategy, discuss.

Read More